Algert Global LLC Buys New Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Algert Global LLC purchased a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 17,158 shares of the company’s stock, valued at approximately $129,000.

Other hedge funds also recently modified their holdings of the company. Benjamin F. Edwards & Company Inc. bought a new stake in Recursion Pharmaceuticals in the 1st quarter valued at $26,000. GAMMA Investing LLC lifted its position in shares of Recursion Pharmaceuticals by 1,588.4% in the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after acquiring an additional 6,036 shares during the period. Amalgamated Bank increased its position in shares of Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after purchasing an additional 2,459 shares during the period. Midwest Financial Group LLC acquired a new position in shares of Recursion Pharmaceuticals in the second quarter valued at $90,000. Finally, Xponance Inc. bought a new position in Recursion Pharmaceuticals in the second quarter worth $98,000. 89.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

RXRX has been the subject of a number of analyst reports. Needham & Company LLC reduced their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. KeyCorp decreased their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Jefferies Financial Group dropped their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Finally, Leerink Partners lowered their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $6.62 on Friday. The stock has a market capitalization of $1.57 billion, a P/E ratio of -4.14 and a beta of 0.80. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 1 year low of $4.97 and a 1 year high of $15.74. The firm has a 50 day moving average of $6.69 and a 200-day moving average of $7.90.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The business had revenue of $14.42 million during the quarter, compared to the consensus estimate of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The company’s revenue for the quarter was up 30.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.38) EPS. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $8.48, for a total value of $97,070.56. Following the completion of the sale, the director now owns 7,155,663 shares in the company, valued at approximately $60,680,022.24. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $8.13, for a total transaction of $48,780.00. Following the transaction, the chief operating officer now owns 535,457 shares of the company’s stock, valued at $4,353,265.41. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $8.48, for a total value of $97,070.56. Following the completion of the sale, the director now owns 7,155,663 shares of the company’s stock, valued at approximately $60,680,022.24. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 201,682 shares of company stock worth $1,353,652 in the last 90 days. Corporate insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.